PTC Therapeutics Inc
NASDAQ:PTCT
| Market Cap (Intraday) | 3.81B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $50.69 |
| 50-Day MA | $40.38 |
| 200-Day MA | $38.67 |
PTC Therapeutics Inc Stock, NASDAQ:PTCT
100 Corporate Court, South Plainfield, New Jersey 07080-2449
United States of America
Phone: +1.908.222.7000
Number of Employees: 1177
Description
PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The firm's portfolio includes Translarna, Emflaza, Tegsedi, Waylivra, and Evrysdi. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.